Pharmaceutical combination and use thereof
US-2024189341-A1 · Jun 13, 2024 · US
US2017290902A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017290902-A1 |
| Application number | US-201615351286-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 14, 2016 |
| Priority date | Nov 22, 2002 |
| Publication date | Oct 12, 2017 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.
Opening claim text (preview).
1 : A composition comprising at least two of the following antigens: (a) a first protein, comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 24 and/or comprising an amino acid sequence consisting of a fragment of at least 7 contiguous amino acids from SEQ ID. NO: 24; (b) a second protein, comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 33 and/or comprising an amino acid sequence consisting of a fragment of at least 7 contiguous amino acids from SEQ ID NO: 33; and (c) a third protein, comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 41 and/or comprising an amino acid sequence consisting of a fragment of at least 7 contiguous amino acids from SEQ ID NO: 41. 2 - 33 . (canceled)
from Pasteurellaceae (F), e.g. Haemophilus influenza · CPC title
Neisseria · CPC title
from Neisseriaceae (F) · CPC title
{Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus · CPC title
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.